Everything below concerns anti-doping category. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Some GSDs have different forms, e.g. infantile, juvenile, adult (late-onset). Some GSDs have different subtypes, e.g. GSD1a / GSD1b, GSD9A1 / GSD9A2 / GSD9B / GSD9C / GSD9D. GSD type 0: Although glycogen synthase deficiency does not result in storage of extra glycogen in the liver, it is classified with the GSDs as type 0 because it is another defect of glycogen storage and can cause similar problems. GSD type VIII (GSD 8): In the past, liver phosphorylase-b kinase deficiency was considered a distinct condition, however it has been classified with GSD type VI and GSD IXa1; it has been described as X-linked recessive inherited. GSD IX has become the dominant classification for this disease, grouped with the other isoenzymes of phosphorylase-b kinase deficiency. GSD type XI (GSD 11): Fanconi-Bickel syndrome (GLUT2 deficiency), hepatorenal glycogenosis with renal Fanconi syndrome, no longer considered a glycogen storage disease, but a defect of glucose transport. The designation of GSD type XI (GSD 11) has been repurposed for muscle lactate dehydrogenase deficiency (LDHA). GSD type XIV (GSD 14): No longer classed as a GSD, but as a congenital disorder of glycosylation type 1T (CDG1T), affects the phosphoglucomutase enzyme (gene PGM1). Phosphoglucomutase 1 deficiency is both a glycogenosis and a congenital disorder of glycosylation. Individuals with the disease have both a glycolytic block as muscle glycogen cannot be broken down, as well as abnormal serum transferrin (loss of complete N-glycans).
It decomposes back to its elements at a temperature of above 523 K (250 °C; 482 °F), and is reduced by water to radon gas and hydrogen fluoride: it may also be reduced back to its elements by hydrogen gas. It has a low volatility and was thought to be RnF2. Because of the short half-life of radon and the radioactivity of its compounds, it has not been possible to study the compound in any detail. Theoretical studies on this molecule predict that it should have a Rn–F bond distance of 2.08 ångströms (Å), and that the compound is thermodynamically more stable and less volatile than its lighter counterpart xenon difluoride (XeF2). The octahedral molecule RnF6 was predicted to have an even lower enthalpy of formation than the difluoride. The [RnF]+ ion is believed to form by the following reaction:
== Medical uses == Relugolix is approved in the United States, Canada and the United Kingdom for the treatment of prostate cancer, in Japan for the treatment of uterine fibroids (uterine leiomyoma) and in the United Kingdom for endometriosis.
== External links == The idea of antiangiogenesis was pioneered by Dr. Judah Folkman. See [1] and [2] Angiogenesis Inhibitors for Cancer – from The Angiogenesis Foundation, 23 June 2009 Angiogenesis Inhibitors for Eye Disease – from The Angiogenesis Foundation, 23 June 2009 Angiogenesis Inhibitors in the Treatment of Cancer – from the National Cancer Institute Angiogenesis+Inhibitors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
The reaction proceeds in three oxidations, each catalysed by the enzyme, which is a cytochrome P450 protein containing heme, isolated from Artemisia annua. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate. The product is used by the plant in the biosynthesis of artemisinin.
Sources: en.wikipedia.org
== Dosage and administration == Each benzhydrocodone/APAP immediate release tablet contains 6.12 mg of benzhydrocodone (equivalent to 6.67 mg of benzhydrocodone hydrochloride) and 325 mg of acetaminophen. The tablets are white, capsule-shaped and are debossed with "KP201" on one side. Dosing should start at one to two tablets every four to six hours, as needed for pain. The dosage should not exceed 12 tablets in a 24-hour period. The total dosage of benzhydrocodone/APAP and any other acetaminophen containing products should not exceed 4000 mg of acetaminophen in a 24-hour period.
CGRP antagonists can be used for both acute migraine treatment as well as prophylactically. CGRP is a neuropeptide which is thought to induce migraines via vasodilation of cranial arteries. CGRP can also release inflammatory agents and cause nervous system sensitization. It is theorized that by antagonizing the CGRP receptor of the trigeminal ganglia, lowered CGRP is released and less migraine occurs. Erenumab is a highly selective human monoclonal antibody which is a promising new development in migraine treatment. It has low risk of hepatoxicity like gepants can have, due to being mostly eliminated via proteolysis. There have been some studies suggesting the benefit of using melatonin for prophylaxis of migraine, however, there is a lack of strength of evidence due to a low number of studies as well as conflicting results. Melatonin has a good safety profile but there have been rare instances of serious side effects. More studies are needed in order to suggest the therapeutic use of melatonin for prophylaxis of migraine.
== Oxygen-17 == Oxygen-17 (17O) is the rarest of the three stable isotopes of oxygen with a low isotopic abundance of about 0.038% = 380 ppm in terrestrial water and air. Naturally 17O is primarily made by burning hydrogen into helium in the CNO cycle, making it a common isotope in the hydrogen burning zones of stars. As the only stable isotope of oxygen possessing a nuclear spin (+5⁄2) and a favorable characteristic of field-independent relaxation in liquid water, through extreme motional narrowing.17O enables NMR studies tracing oxidative metabolic pathways (i.e. conversion of 17O2 gas to metabolically produced H217O water by oxidative phosphorylation in mitochondria) at high magnetic fields. This is a necessary requirement to overcome the low SNR from low abundance, low gyromagnetic ratio and fast quadrupolar transversal relaxation in contrast to proton/hydrogen, which is the most commonly used nucleus in magnetic resonance. Water used as nuclear reactor coolant is subjected to intense neutron flux. Natural water starts out with 0.038% of 17O; heavy water starts out incidentally enriched to about 0.055% in that isotopes. Further, the neutron flux slowly converts 16O in the cooling water to 17O by neutron capture, increasing its concentration. The neutron flux slowly converts 17O (with much greater cross section) in the cooling water to carbon-14, an undesirable product that can escape to the environment:
== In popular culture == The use of iodine-131 as a poison – used in small doses over a period of time to disrupt a person's ability to think and tell right from wrong – played a central role in the episode "The Case of the Melancholy Marksman" of the long-running CBS TV series Perry Mason (season 5, episode 24, first broadcast March 24, 1962).
Some suspected that after finishing the conscripted aerodrome work, they might be drafted to fight overseas. Rumours to this effect abounded enough that the chief native commissioner, H H D Simmonds, distributed a circular in November 1940 instructing the commissioners to make clear that the drafted men were required for labour only. Voluntary employment increased sharply during 1940 and 1941, both among indigenous blacks and migrant labourers, but many white farmers still complained about a lack of manpower. A severe drought during the 1941–42 season led to a food shortage in the colony, prompting the passing in June 1942 of the Compulsory Native Labour Act, under which unemployed black males between 18 and 45 years of age could be conscripted for work on white-owned farms. Announcing the act, Tredgold—by now Minister of Native Affairs in addition to Defence and Justice—commented that its "principle ... would be intolerable under ordinary circumstances", but that the war made it necessary. The act required each draftee to work at least three months at 15s/- per month; the pay rose to 17s/6 if he agreed to stay a further three months. This conscription of labour contributed to the rise in the country's overall agricultural yield, but had a negative impact on the localised production of many kraals, either because too many men had been drafted for work elsewhere or because they had fled to avoid it. The scheme continued until the act's repeal in 1946.
Sources: en.wikipedia.org
== Uterine leiomyomas vs. uterine leiomyosarcomas == Leiomyomas are benign smooth muscle tumors that have overlapping features with leiomyosarcomas. Although both originate from smooth muscle, leiomyomas do not, in contrast, mature into leiomyosarcomas. Leiomyomas are seen in premenopausal women and are symptomatic 20–50% of the time, while leiomyosarcomas, the most common uterine sarcomas, are seen in older postmenopausal women, with 40-60 being the peak age incidence. Since leiomyomas are benign and mostly asymptomatic, minimally invasive treatment modalities are used to treat them. For this same reason, distinguishing them from LMSs before surgical procedures is crucial to ensure that laparoscopic procedures or diagnosis delay will not lead to heightened morbidity given the poor prognosis of LMS. For example, the FDA has warned against using morcellation for benign leiomyomas, as those with unsuspected sarcomas are at risk of cancer spread.
In continuum mechanics, viscosity is a property of a fluid that quantifies the resistance force acting on fluids when there is relative motion between fluid parcels. This resistance force is caused by the stress in fluid parcels, which ideally is directly proportional to the strain rate (the time derivative of strain) that arises when fluid parcels are in relative motion, and the relative speed between the boundary between adjacent fluid parcels is zero. In liquids, viscosity arises from cohesive molecular forces, while in gases it results from molecular collisions. Except for the case of superfluidity, there is no fluid with zero viscosity, and thus all fluid flows involve viscous effects to some degree. For liquids, it corresponds to the informal concept of thickness; for example, syrup has a higher viscosity than water. Viscosity is defined scientifically as a force multiplied by a time divided by an area. Thus its SI units are newton-seconds per metre squared, or pascal-seconds. For instance, when a viscous fluid is forced through a tube, it flows more quickly near the tube's center line than near its walls. Some stress (such as a pressure difference between the two ends of the tube) is needed to sustain the flow. This is because a force is required to overcome the friction between the layers of the fluid which are in relative motion. For a tube with a constant rate of flow, the strength of the compensating force is proportional to the fluid's viscosity. In general, viscosity depends on a fluid's state, such as its temperature, pressure, and rate of deformation.
Marcus (1948), cardiologist and professor at University of Arizona Medical Center Frederick Reif (1948), professor of physics and psychology at Carnegie Mellon University, recipient of the 1994 Robert A. Millikan Award Robert Neil Butler (1949), president of the International Longevity Center and winner of the Pulitzer Prize for General Nonfiction William Chinowsky (1949), astrophysicist and professor at the University of California, San Diego Edgar Housepian (1949), neurosurgeon, co-founder of the Fund for Armenian Relief Benjamin Widom (1949), professor of chemistry at Cornell University; recipient of the Boltzmann Medal in 1998 Noel Corngold (1950), physicist at California Institute of Technology Edwin Kessler (1950), first director of the National Severe Storms Laboratory Gerald Weissmann (1950), cell biologist, liposome inventor, essayist Arthur H. Westing (1950), ecologist and researcher at Stockholm International Peace Research Institute Leon Cooper (1951), winner of the Nobel Prize in Physics in 1972 Richard A. Gardner (1952), psychiatrist known for researching Parental alienation syndrome Edgar Haber (1952), former president of Bristol-Myers Squibb and professor at Harvard Medical School Donald E.
In 2024, SIUT acquired a four-star Pakistani hotel, Regent Plaza Hotel, to convert it into a health care facility. The Regent Plaza hotel was located on Shahrah-e-Faisal, consisting an plot area of 13,200 square yards, with construction having a total covered area of 47,034 square yards. SIUT acquired the Regent Plaza from Pakistan Hotels Developers Limited for PKR 14.5 billion.
Ribosomally synthesized and post-translationally modified peptides (RiPPs), also known as ribosomal natural products, are a diverse class of natural products of ribosomal origin. Consisting of more than 20 sub-classes, RiPPs are found in all three domains of life, and they possess a wide range of biological functions. As a consequence of the falling cost of genome sequencing, scientific interest in RiPPs has increased in the last few decades. Because RiPPs are more closely predictable from raw genomic data than other natural products (e.g. alkaloids and terpenoids), their presence in sequenced organisms can, in theory, be identified rapidly. This makes RiPPs an attractive target of modern natural product discovery efforts.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.